Recently, Jiangsu Province announced the first batch of private technology enterprises for 2022, and Linaxin Biotechnology was successfully selected and awarded the title of "Jiangsu Province Private Technology Enterprise". Private technology enterprises are an important component of the country's advanced technology industry and have become a significant growth point for economic development across the country.

The qualification review of private technology enterprises in Jiangsu Province has strict conditions. According to the "Guidelines for Filing of Private Technology Enterprises in Jiangsu Province (Trial)", private technology enterprises should rely on a certain number of scientific and technological personnel to continuously conduct research and development and technology achievement transformation activities in the "National Key Supported High tech Fields", form core independent intellectual property rights, and carry out continuous production and operation activities based on this. They should be non-state-owned controlled private enterprises registered in accordance with the law in the administrative area of Jiangsu Province.

The achievement of this honor is a recognition and affirmation of Linaxin Biotechnology's independent innovation and achievement transformation capabilities.

At present, Linaxin Biotechnology personnel account for 70%, and master's and doctoral personnel account for 28%, which can effectively support the company to continuously improve its independent research and development level and innovation capabilities. The company adheres to the key strategy of "healthy home, precise early screening" and will release its self-developed product - the home warning self-test device "Changle Xin" in 2022 ™️” And 'Chang Wei Le' ™️”， No need to control diet, achieve home self-test, and check the hidden blood in the upper and lower digestive tract in 20 seconds, truly achieving prevention and testing without leaving home, which has attracted widespread attention from the industry and market.

In the future, Linaxin Biotechnology will continue to leverage and enhance its advantages in the fourth generation nanopore cancer early screening, combining advanced cancer early screening home self inspection platforms with big data technology to contribute to the "Strong, Rich, Beautiful and High" new Jiangsu health.